Spectral density of Barkhusen noise in FINEMET-type materials

L

Studia Litteraria

Barta János, Géniuszok találkozása, Petőfi és Arany barátsága, 3-32. Sonkoly István, Megzenésített Petőfi-versek, 33-50. Pálfy G. István, A Tempefői dramaturgiája, 51-62. Görömbei András, Csokonai és a honfoglalási eposz, 63-76. Bárczi Klára, A népiesség Csokonai és Burns költészetében, 77-92. Julow Viktor, Csokonai és Petőfi között, A debreceni késő-felvilágosodásról, 93-106. Tóth Béla, Maróthi György albuma, 107-126. Deme Zoltán, Verseghy és a jambusi kettős ritmus, 127-136. Péterffy Ida, Kováts Sámuel, Csokonai jó barátja, 137-155

Distribution and habitat preference of Buxbaumia Hedw. species in Hungary

The genus Buxbaumia includes two species (B. aphylla and B. viridis) in Hungary. Both of them were thought to be rare and threatened: B. aphylla was rated as Vulnerable (VU), while B. viridis as Endangered (EN) on the national Red List. The latter is a Natura 2000 species and protected by law in the country. The aims of the research were to summarize the historical and actual distribution of these taxa and to reveal their habitat preference, population size and phenology in Hungary. During systematic surveys from 2014 to 2017, we have checked previously known localities and similar habitats in several Hungarian landscapes. In almost every newly discovered stand, phytocoenological relevés were taken in 1 m2 plots. We recorded here the number, state and maximal density (plant/1 dm2) of the individuals (sporophytes or setae), and listed the presence of cooccurring species. The cover values of moss layer, bare surfaces and organic debris were estimated; the exposure and the inclination were measured. We have found some formerly known and many more newly discovered populations of Buxbaumia species. Although B. viridis is usually considered to be an epixylic bryophyte, both species occurred mostly on soil, on steep, north-facing slopes, in stands of acidophilous communities. However, B. aphylla was more common in drier acidophytic oak forests, while B. viridis preferred acidophytic beech forests. In both cases, the most frequent (fr.≥50%) co-occurring mosses were Dicranella heteromalla, Dicranum scoparium, Hypnum cupressiforme and Polytrichum formosum. According to the observed habitat preference and using MÉTA maps, we presume further potential occurrences of shield-mosses in Hungary, mainly in hilly regions. Since more than 1600 individuals and 160 (usually stable) stands of both taxa were discovered recently in the country, we suggest that their threat status should be lowered to Near Threatened (NT) in the next Bryophyte Red List of Hungary. Whereas the characteristics of B. aphylla are similar to those reported in the literature, our results on the habitat preference of B. viridis greatly differ from the Hungarian and international published accounts. Our new observations will be relevant for the protection of B. viridis in the future

Treatment of relapsing multiple sclerosis in Hungary – consensus recommendation from the Hungarian neuroimmunology society

Multiple sclerosis (MS) may impact quality of life, careers and family plans of the affected individuals. The current treatments with disease modifying therapies aim to prevent people with MS (pwMS) from disability accumulation and progression. Different countries have different reimbursement policies resulting in inequalities in patient care among geographical regions. Access to anti-CD20 therapies for relapsing MS is restricted in Hungary because therapy of individual cases only is reimbursed. In the light of the latest research and national guidelines, 17 Hungarian MS experts agreed on 8 recommendations regarding relapsing pwMS using the Delphi round method. Strong agreement (> 80%) was achieved in all except one recommendation after three rounds, which generated a fourth Delphi round. The experts agreed on treatment initiation, switch, follow-up and discontinuation, as well as on special issues such as pregnancy, lactation, elderly population, and vaccination. Well-defined national consensus protocols may facilitate dialogue between policymakers and healthcare professionals and thus contribute to better patient care in the long run